MD3658552T2 - Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil - Google Patents

Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil

Info

Publication number
MD3658552T2
MD3658552T2 MDE20200593T MDE20200593T MD3658552T2 MD 3658552 T2 MD3658552 T2 MD 3658552T2 MD E20200593 T MDE20200593 T MD E20200593T MD E20200593 T MDE20200593 T MD E20200593T MD 3658552 T2 MD3658552 T2 MD 3658552T2
Authority
MD
Moldova
Prior art keywords
morpholinophenyl
pyrazol
pyrimidin
acrylamide
dimethylamino
Prior art date
Application number
MDE20200593T
Other languages
English (en)
Inventor
Sang-Ho Oh
Ja-Heouk Khoo
Jong-Chul Lim
Seong-Ran Lee
Hyun Ju
Woo-Seob Shin
Dae-Gyu Park
su-min Park
Yoon-Ah Hwang
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65040211&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3658552(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MD3658552T2 publication Critical patent/MD3658552T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/22—Tin compounds
    • C07F7/2284—Compounds with one or more Sn-N linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Prezenta invenţie furnizează un procedeu îmbunătăţit pentru prepararea derivaţilor de aminopirimidină sau a sărurilor acceptabile farmaceutic ale acestora care au o activitate inhibitorie selectivă asupra kinazelor, în special asupra kinazelor proteice pentru receptorii factorului de creştere epidermal. Şi de asemenea, prezenta invenţie furnizează noi intermediari, utili pentru respectivul procedeu, şi procedee pentru preparea acestora.
MDE20200593T 2017-07-28 2018-07-25 Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil MD3658552T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170096212 2017-07-28
PCT/KR2018/008379 WO2019022485A1 (en) 2017-07-28 2018-07-25 IMPROVED PROCESS FOR THE PREPARATION OF AMINOPYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
MD3658552T2 true MD3658552T2 (ro) 2024-02-29

Family

ID=65040211

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20200593T MD3658552T2 (ro) 2017-07-28 2018-07-25 Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil

Country Status (31)

Country Link
US (4) US10889578B2 (ro)
EP (1) EP3658552B1 (ro)
JP (2) JP7228562B2 (ro)
KR (1) KR20190013553A (ro)
CN (2) CN111315742B (ro)
AU (2) AU2018308038B2 (ro)
BR (1) BR112020001278A2 (ro)
CA (1) CA3070069C (ro)
CO (1) CO2020000374A2 (ro)
DK (1) DK3658552T3 (ro)
EA (1) EA202090383A1 (ro)
ES (1) ES2962961T3 (ro)
FI (1) FI3658552T3 (ro)
HR (1) HRP20231191T1 (ro)
HU (1) HUE063533T2 (ro)
IL (2) IL271973B (ro)
LT (1) LT3658552T (ro)
MA (1) MA49700B1 (ro)
MD (1) MD3658552T2 (ro)
MX (1) MX2022008743A (ro)
NZ (1) NZ761156A (ro)
PH (1) PH12020500059A1 (ro)
PL (1) PL3658552T3 (ro)
PT (1) PT3658552T (ro)
RS (1) RS64654B1 (ro)
SA (1) SA520411112B1 (ro)
SG (1) SG11201913517UA (ro)
SI (1) SI3658552T1 (ro)
UA (1) UA125317C2 (ro)
WO (1) WO2019022485A1 (ro)
ZA (1) ZA202001250B (ro)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL271973B (en) * 2017-07-28 2022-08-01 Yuhan Corp An improved process for the preparation of aminopyrimidine derivatives
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
NZ533118A (en) 2001-11-27 2006-07-28 Wyeth Corp 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
ES2633318T3 (es) 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
KR101892989B1 (ko) * 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
WO2011046970A1 (en) 2009-10-12 2011-04-21 Myrexis, Inc. Amino - pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon
EA024729B1 (ru) * 2009-11-13 2016-10-31 Джиноско Киназные ингибиторы
CN102762208A (zh) 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环
US20130196990A1 (en) 2010-10-06 2013-08-01 Junya Qu Benzimidazole Derivatives As PI3 Kinase Inhibitors
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
EP2651939B1 (en) 2010-12-13 2015-04-08 Array Biopharma, Inc. SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
CN105254616B (zh) 2011-07-27 2017-10-17 阿斯利康(瑞典)有限公司 取代的n‑(2‑甲氧基‑5‑硝基苯基)嘧啶‑2‑胺化合物及其盐
US20130165464A1 (en) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
SG11201402765TA (en) 2011-12-30 2014-06-27 Hanmi Pharm Ind Co Ltd THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
CN104860891B (zh) 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物
CN106687457B (zh) 2014-05-13 2020-01-10 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
WO2015188777A1 (en) 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
AU2015331166B2 (en) * 2014-10-13 2018-04-26 Yuhan Corporation Compounds and compositions for modulating EGFR mutant kinase activities
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR102263A1 (es) 2015-10-14 2017-02-15 Yuhan Corp Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante
DE102017212159A1 (de) 2017-07-14 2019-01-17 Krones Aktiengesellschaft Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden
IL271973B (en) * 2017-07-28 2022-08-01 Yuhan Corp An improved process for the preparation of aminopyrimidine derivatives
RS64545B1 (sr) 2017-07-28 2023-09-29 Yuhan Corp Postupak za pripremu n-(5-(4-(4-formil-3-fenil-1h-pirazol-1-il)pirimidin-2-ilamino)-4-metoksi-2-morfolinofenil)akrilamida
CN108826170A (zh) 2018-06-26 2018-11-16 深圳市远润欣电子有限公司 局部全般照明的模式、控制方法及台灯

Also Published As

Publication number Publication date
AU2018308038B2 (en) 2022-02-03
MA49700B1 (fr) 2023-09-27
IL292429B1 (en) 2023-05-01
US20220281861A1 (en) 2022-09-08
AU2022202936A1 (en) 2022-05-26
PT3658552T (pt) 2023-11-03
RS64654B1 (sr) 2023-10-31
UA125317C2 (uk) 2022-02-16
PL3658552T3 (pl) 2024-02-19
DK3658552T3 (da) 2023-11-20
IL292429A (en) 2022-06-01
JP7228562B2 (ja) 2023-02-24
AU2022202936B2 (en) 2023-04-27
EA202090383A1 (ru) 2020-06-15
HRP20231191T1 (hr) 2024-02-02
US10889578B2 (en) 2021-01-12
WO2019022485A1 (en) 2019-01-31
JP2020528440A (ja) 2020-09-24
CN111315742B (zh) 2023-09-01
CO2020000374A2 (es) 2020-05-05
BR112020001278A2 (pt) 2020-07-21
AU2018308038A1 (en) 2020-01-30
EP3658552A4 (en) 2021-06-23
CA3070069A1 (en) 2019-01-31
EP3658552A1 (en) 2020-06-03
IL271973B (en) 2022-08-01
US11286253B2 (en) 2022-03-29
NZ761156A (en) 2024-01-26
CA3070069C (en) 2024-02-20
PH12020500059A1 (en) 2020-09-28
US11708362B2 (en) 2023-07-25
KR20190013553A (ko) 2019-02-11
FI3658552T3 (fi) 2023-11-16
JP2023027091A (ja) 2023-03-01
CN116987112A (zh) 2023-11-03
HUE063533T2 (hu) 2024-01-28
US20200165236A1 (en) 2020-05-28
SA520411112B1 (ar) 2022-02-21
MA49700A (fr) 2021-03-17
SI3658552T1 (sl) 2023-11-30
SG11201913517UA (en) 2020-02-27
ZA202001250B (en) 2023-04-26
EP3658552B1 (en) 2023-09-13
ES2962961T3 (es) 2024-03-22
IL292429B2 (en) 2023-09-01
IL271973A (en) 2020-02-27
LT3658552T (lt) 2023-11-27
MX2022008743A (es) 2023-02-02
US20230312545A1 (en) 2023-10-05
US20210269427A1 (en) 2021-09-02
CN111315742A (zh) 2020-06-19

Similar Documents

Publication Publication Date Title
MD3658552T2 (ro) Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil
NZ750290A (en) Amino pyrimidine ssao inhibitors
CY1123796T1 (el) Στερεες μορφες μιας ενωσης που τροποποιει κινασες
PH12018502151A1 (en) Heterocyclic amides useful as protein modulators
MD3687996T2 (ro) Săruri de derivați de pirolotriazină utile ca inhibitori TAM
EA200700142A1 (ru) Замещенные гетероциклом циклические производные мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
ATE447562T1 (de) Verstärker von glutamat-rezeptoren
CY1113244T1 (el) Ενωση ουρακιλης η οποια εχει ανασταλτικη δραστικοτητα σε ανθρωπινη τριφωσφαταση δεοξυουριδινης ή αλας αυτης
MX2022015558A (es) Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino ) pirimidin-4-il) benzamida.
PH12020500093A1 (en) Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
MX2017013248A (es) Compuesto del inhibidor fgfr4 cristalino y usos del mismo.
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
EA201992744A1 (ru) Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей
CO2020003977A2 (es) Compuesto de heteroarilo con contenido de nitrógeno, y su uso farmacéutico
MX2021008632A (es) Moléculas cíclicas como inhibidores de la tirosina cinasa de bruton.
SA520411120B1 (ar) مركبات وسيطة مبتكرة مفيدة لتركيب مشتقات الأمينوبيريميدين، وعملية لتحضير هذه المركبات الوسيطة، وعملية لتحضير مشتقات الأمينوبيريميدين باستخدام هذه المركبات
PH12018502668A1 (en) Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
EA200602154A1 (ru) Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5
MX2020004148A (es) Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf).
TH2001000453A (th) สารระหว่างกลางชนิดใหม่ที่มีประโยชน์สำหรับการสังเคราะห์อนุพันธ์อะมิโนไพริมิดีนกระบวนการสำหรับเตรียมสิ่งดังกล่าวและกระบวนการสำหรับเตรียมอนุพันธ์อะมิโนไพริมิดีนโดยใช้สิ่งดังกล่าว
AU2018375456A1 (en) Thieno(3,2-d)pyrimidine compound having inhibitory activity for protein kinase
EA201892261A1 (ru) Гетероциклические амиды, пригодные в качестве модуляторов белков
MX2021010016A (es) Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.